Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

3,029

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
GERD
Interventions
DRUG

esomeprazole (Nexium®)

"This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"

DRUG

Xolaam®

"This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"

Trial Locations (1)

Unknown

Research Site, Rouen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY